Research Evidence / Overview of Studies for Deso 20
Evidence for Use in Contraception (Pregnancy Prevention)
The primary research for Deso 20 (Desogestrel and Ethinylestradiol) was conducted to evaluate its use in contraception. Large-scale Phase 3 clinical trials was studied for this purpose over periods typically ranging from 12 to 18 cycles of use. These studies was evaluated in healthy, sexually active women of childbearing age to measure the occurrence of pregnancy. The main outcome research examined in these pivotal trials was the Pearl Index, which describes the number of pregnancies that occurred per 100 women over one year of use.
These pivotal trials data show patterns related to the establishment of regular withdrawal bleeding patterns, a pattern that was monitored during the studies. Regulatory bodies reviewed these trial measurements of the Pearl Index, along with findings from large, post-approval observational studies that were observed in real-world usage settings, when determining the permissible indications for the product. These findings contribute to the broader evidence landscape that characterizes the observed rate of pregnancy prevention.
However, the real-world observed outcomes of any oral contraceptive may vary from the trial measurements. Trial results typically reflect the study results reflect the specific conditions under which they were conducted, where adherence is carefully monitored. The long-term observed pregnancy rate (typical-use rate) is heavily influenced by factors outside the research, such as consistent daily use, which means the evidence contributes to understanding symptom patterns but research does not determine whether an individual will respond similarly.
Evidence for Menstrual Symptom Management
The research base extends beyond pregnancy prevention to explore how Deso 20 was studied for conditions characterized by fluctuating or episodic manifestations related to the menstrual cycle, such as painful and heavy periods. The evidence available for these uses often comes from randomized controlled trials (RCTs) and comprehensive systematic reviews that examined the Combined Oral Contraceptive (COC) class overall, including formulations containing Desogestrel.
Study Structure for Painful Periods (Dysmenorrhea)
Research exploring how symptoms change over time in women experiencing painful menstruation was evaluated in specific clinical trials. These studies applied in studies examining patient-reported experiences of outcomes related to physical discomfort. The trials monitored changes in pain severity, often using scales like the Visual Analogue Scale (VAS), and monitored the participants' use of additional pain medication over defined time intervals, typically 3 to 6 cycles.
The trials studies report how symptoms evolved in the observed populations, finding patterns that may indicate changes in physical discomfort during the study period. However, the evidence quality varies across studies, and much of the high-level evidence is limited to COCs as a general class, making specific conclusions about Deso 20 versus other COCs or a placebo for this condition certainty remains low.
Study Structure for Heavy Bleeding (Menorrhagia)
Studies research examined conditions associated with acute or disruptive episodes of heavy menstrual bleeding. These trials was observed in populations with heavy bleeding and focused on outcomes monitoring physiological strain or stress. The primary outcomes measured included objective or semi-objective assessment of menstrual blood loss volume, such as using the Pictorial Blood Assessment Chart (PBAC), and corresponding changes in blood markers like hemoglobin levels, typically monitored over 6 to 12 cycles.
These research efforts findings describe patterns observed in the studies where measurements for blood loss volume were associated with lower observed levels compared to pre-treatment periods. This evidence contributes to understanding symptom patterns related to systemic or functional imbalance. However, comparative evidence is lacking against all possible treatment alternatives for heavy bleeding. Furthermore, the reliance on subjective charting (PBAC) in some studies means that evidence quality varies across studies.
Long-Term Study Duration and Follow-up Data
The longest duration of prospective, controlled research for Deso 20 typically spans 12 to 18 cycles for primary evaluation of pregnancy occurrence. This means that formal, long-term controlled data (beyond 1.5 years) is limited. After initial trials conclude, continued information gathering moves to less controlled methods. Research describes the patterns observed in large, observational studies that were observed in general user populations over multiple years. While these studies provide essential context regarding long-term usage, they are less controlled than the initial randomized trials, and therefore, long-term effects are not fully established and evidence quality varies across studies.
Evidence in Specific Populations
The primary clinical research for Deso 20 was evaluated in women of reproductive age, generally between 18 and 40 years old. Results apply only to the populations studied, and the data specifically addressing women at the younger or older ends of the childbearing spectrum, particularly those with complex comorbidities or severe underlying conditions, data for certain groups remain insufficient. The research exploring non-contraceptive study endpoints (dysmenorrhea and menorrhagia) was evaluated in women who had those conditions. However, the comparative evidence is lacking when trying to assess how this specific formulation can compare with others in specific, small subgroups defined by disease severity or other health factors.
Areas of Research Uncertainty and Study Gaps
The evidence base, while extensive for the primary purpose of contraception, has several limitations and areas where data are still emerging:
- Follow-up durations were limited in controlled trials, meaning the long-term patterns of both the observed pregnancy rate and cycle control rely heavily on less controlled, observational data.
- Subgroup findings are uncertain, as the main studies focused on broad populations, and detailed, well-powered data for specific racial, ethnic, or medical subgroups is limited.
- Findings were mixed regarding patterns of unscheduled (breakthrough) bleeding, especially during the initial adjustment period. The specific factors that predict persistent, bothersome unscheduled bleeding in individual users are not fully established.
- Evidence is limited for directly comparing Deso 20 to every other existing hormonal contraceptive, as many studies focus on regulatory requirements for initial evaluation rather than head-to-head comparisons for secondary outcomes.
Key Studies & References
- Management of heavy menstrual bleeding: NICE Guideline NG88 (Summary of clinical evidence and outcomes studied)
